Summit Therapeutics Inc. Share Price

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - 01:30:00 14/10/2026 am IST 5-day change 1st Jan Change
15.52 USD -9.40% Intraday chart for Summit Therapeutics Inc. -10.34% -11.26%

Valuation: Summit Therapeutics Inc.

Market Cap 936.94Cr 1.24TCr 1.11TCr 1.03TCr 1.76TCr 1,17800Cr 1.78TCr 12TCr 4.85TCr 61TCr 4.66TCr 4.56TCr 1,96600Cr P/E 2026 *
-13.5x
P/E 2027 * -13.3x
Enterprise Value 889.95Cr 1.18TCr 1.05TCr 981.61Cr 1.67TCr 1,11900Cr 1.69TCr 12TCr 4.6TCr 58TCr 4.43TCr 4.33TCr 1,86800Cr EV / Sales 2026 *
3,032x
EV / Sales 2027 * 219x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
22/09 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
15/09 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
15/09 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
10/09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09/09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
26/08 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
26/08 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
26/08 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
26/08 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
25/08 Wall Street Wants Receipts Zonebourse
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day-9.40%
1 week-10.34%
Current month-8.22%
1 month-11.57%
3 months+1.44%
6 months-22.52%
Current year-11.26%
1 week 15.46
Extreme 15.465
17.64
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-9.40%-10.34%-32.32%+823.81% 1.37TCr
-0.32%-5.97%+57.78%+74.48% 7.06TCr
-1.99%-13.92%+3.01%+51.60% 5.12TCr
-1.32%-1.70%+6.99%+35.47% 4.8TCr
-0.58%+0.27%+27.93%+30.76% 4.32TCr
-2.84%-5.72%+286.54%+530.02% 4.16TCr
-0.38%-3.78%+6.74%+95.25% 3.98TCr
-0.39%-1.48%+10.41%+43.19% 3.09TCr
-2.66%-11.49%+42.12%+4.38% 2.75TCr
-7.13%-7.02%-12.99%-14.07% 2.41TCr
Average -2.70%-5.33%+39.62%+167.49% 3.91TCr
Weighted average by Cap. -1.87%-5.17%+47.82%+125.85%

Financials

2026 *2027 *
Net sales 29.35L 38.88L 34.73L 32.37L 55.24L 37Cr 55.67L 3.88Cr 1.52Cr 19Cr 1.46Cr 1.43Cr 62Cr 4.19Cr 5.55Cr 4.96Cr 4.62Cr 7.88Cr 526.65Cr 7.94Cr 55Cr 22Cr 273.9Cr 21Cr 20Cr 878.91Cr
Net income -70Cr -93Cr -83Cr -77Cr -131.85Cr -8.81TCr -132.88Cr -925.72Cr -362.39Cr -4.58TCr -348.55Cr -340.91Cr -15TCr -74Cr -98Cr -88Cr -82Cr -139.83Cr -9.34TCr -140.93Cr -981.77Cr -384.33Cr -4.86TCr -369.66Cr -361.55Cr -16TCr
Net Debt -47Cr -62Cr -56Cr -52Cr -88Cr -5.91TCr -89Cr -620.93Cr -243.07Cr -3.07TCr -233.79Cr -228.66Cr -9.86TCr -20Cr -27Cr -24Cr -22Cr -38Cr -2.52TCr -38Cr -264.43Cr -103.52Cr -1.31TCr -100Cr -97Cr -4.2TCr
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
13/26/13 $15.52 -9.40% 71,18,789
12/26/12 $17.13 -2.62% 43,75,906
09/26/09 $17.59 +2.45% 57,55,325
08/26/08 $17.17 -4.35% 61,79,332
07/26/07 $17.95 +3.70% 81,75,297
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
11.72GBP
Average target price
22.51GBP
Spread / Average Target
+92.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock